For the assessment of the antitumor efficacy of the additional anti-EGFR antibody to cytotoxic regime-based CCRT, a phase II study demonstrated the clinical efficiency of treating locoregionally advanced NPC patients with concurrent cetuximab, cisplatin, and IMRT in stage III, IVa, and IVb (according to the AJCC 7th edition staging system) NPC patients. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.